ResMed
374 hedge funds and large institutions have $6.25B invested in ResMed in 2017 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 148 increasing their positions, 123 reducing their positions, and 35 closing their positions.
250% more funds holding in top 10
Funds holding in top 10: 2 → 7 (+5)
60% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 35
26% more call options, than puts
Call options by funds: $6.96M | Put options by funds: $5.52M
20% more repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 123
14% more capital invested
Capital invested by funds: $5.47B → $6.25B (+$784M)
4% more funds holding
Funds holding: 361 → 374 (+13)
1.14% less ownership
Funds ownership: 62.5% → 61.37% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$905M |
| 2 |
Morgan Stanley
New York
|
+$38M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.1M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$26.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$56.2M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$51.8M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$44.3M |
| 4 |
Renaissance Technologies
New York
|
-$24.4M |
| 5 |
KI
Kalmar Investments
Greenville,
Delaware
|
-$21.3M |
RMD Hedge Fund Activity: Q1 2017 in Review
374 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q1 2017, worth a combined $6.25B — up 14% from $5.47B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new RMD positions and 35 closed out — a net gain of 21 holders — while 148 added to existing stakes and 123 trimmed.
The largest buyer was BlackRock, adding an estimated $905M. The largest seller was Panagora Asset Management, cutting an estimated $56.2M.
- 374 institutional investors held ResMed (RMD) as of Q1 2017, up from 361 in Q4 2016.
- Funds reported $6.25B of ResMed stock for Q1 2017, up 14% quarter-over-quarter.
- 56 funds opened new ResMed positions in Q1 2017 and 35 closed out, a net change of +21 holders.
- The largest ResMed buyer in Q1 2017 was BlackRock, an estimated $905M added.
- The largest ResMed seller in Q1 2017 was Panagora Asset Management, an estimated $56.2M sold.
Based on aggregated 13F filings for Q1 2017.